Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

Neurology

Volumn 47, Issue 4, 1996, Pages 1085-1087

  Wolters, E Ch ^a,d   Jansen, E N H ^b   Tuynman Qua, H G ^c   Bergmans, P L M ^a  

^a Amsterdam University Medical Center   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c Eli Lilly Nederland   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CLOZAPINE; LEVODOPA; OLANZAPINE; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSION; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GRANULOCYTOPENIA; HALLUCINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SCORING SYSTEM; SLEEP DISORDER;

EID: 0029845563     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.4.1085     Document Type: Article

References (10)

1. Wolters ECh, Tuynman-Qua HG. Dopaminometic psychosis: the role of atypical neuroleptics. In: Alberca R, Ochoa JJ, eds. Pautas actualis en el tratamiento medico y quirurgico de la enfermedad de Parkinson. Barcelona: Inter-Congrés, 1995:257-268.
2. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol 1991;14:283-295.
3. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-434.
4. Wolters ECh, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40:832-834.
5. Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994;343:1370-1371.
6. Lang AE, Sandor P, Duff J. Remoxipride in Parkinson's disease: differential response in patients with dyskinesia fluctuations versus psychosis. Clin Neuropharmacol 1995;18:39-45.
7. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994;344:681.
8. Wong DT, Calligaro DO, Bymaster FP, Moore NA, Seeman P. Preclinical pharmacology of olanzapine: a novel antipsychotic agent. Presented at the Ninth World Congress of Psychiatry; June 6-12, 1993; Rio de Janeiro, Brazil.
9. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study. Ann Neurol 1983;14: 136-140.
10. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43: 2227-2229.